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To the Editor
We have read with great interest the hypothesis article writ-
ten by Dr. O. Wess concerning “A neural model for chronic
pain and pain relief by extracorporeal shock wave treat-
ment” (ESWT) published recently in Urological Research
[1]. We would like to express to the readers of Urological
Research our concerns about the content and concept of this
article.
We believe, a clear warning should be expressed to your
readership. On page 328 of his article, Dr. Wess [1] states
“This treatment regime or a similar one is used for chronic
pelvic pain as well as shoulder pain, heel spur and angina
pectoris for example.” This statement is made without any
reference and might imply to readers that ESWT is an
equally accepted treatment modality for these very diVerent
indications. However, this is not the case.
ESWT has become a well-established treatment opportu-
nity for several diseases of the musculoskeletal system such
as chronic plantar fasciitis [2, 3], chronic Achilles tendin-
opathy [4–6] and chronic lateral epicondylitis (“tennis ell-
bow”; [7–9]). On the other hand, experience with ESWT as
a treatment regime for chronic pelvic pain syndrome or
angina pectoris can be regarded only experimentally to date
[10, 11], or for that matter, anecdotally. The casual use of
ESWT in the treatment of angina pectoris could result in
unwanted side eVects such as arterial embolisms or even
severe damage of the lung.
Our major concern, however, is linked to Section “Asso-
ciative memory model for establishing reXex functions” of
Dr. Wess’ article [1]. This section outlines in one and half
pages, a hypothesis of so-called “associative pain mem-
ory”, without so much as a reference to the literature. An
essential part of this model is the idea of separating pain
from pathology, as expressed in the following sentences by
Dr. Wess [1]:
• “Chronic pain, for example, without underlying anatomi-
cal disorders is considered a pathological control func-
tion” (p. 328, right column, lines 12 V);
• “In cases of chronic pain without organic reasons […]”
(p. 329, right column, line 24); and
• “Therapeutic treatment modalities are no more focused
on speciWc organs under pain but on pain memory”
(p. 329, right column, lines 33 V).
Further, in Section “Hypothetic mechanism of shock wave
therapy” Dr. Wess writes [1]:
• “The problem seems to be too complex for a simple
answer since the location of the pathology is considered
not in the painful organ itself anymore but is diVusely
spread over extended areas as well as over several levels
of the PNS/CNS.” (peripheral nervous system/central
nervous system) (p. 331, right column, lines 7 V).
In this regard, the following questions arise:
1. Is this really the Weld of ESWT, i.e., are users of ESWT
really treating “pain without underlying anatomical
disorders”, and are they “no more focused on speciWc
organs under pain but on pain memory”?
2. Are molecular and cellular mechanisms known as to
how extracorporeal shock waves might mediate their
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pain-relieving action on anatomical disorders of the
musculoskeletal system?
3. If users of ESWT are treating anatomically deWned dis-
orders and the potential underlying molecular and cel-
lular mechanisms are known, what might have been
Dr. Wess’ [1] motivation to publish his hypothesis
without reference to this knowledge?
It is beyond the scope of this letter to provide comprehen-
sive answers to these questions. However, the following
appears essential:
1. ESWT is not used in the international peer-reviewed
literature to treat “pain without underlying anatomical
disorders”, and ESWT cannot be regarded “no more
focused on speciWc organs under pain but on pain
memory”. This can be deduced easily from the titles of
recent prospective, randomized, controlled clinical tri-
als using ESWT published in the international peer-
reviewed literature, such as:
• “Radial extracorporeal shock wave therapy is safe and
eVective in the treatment of chronic recalcitrant plan-
tar fasciitis: results of a conWrmatory randomized pla-
cebo-controlled multicenter study.” [3];
• “Eccentric loading, shock wave treatment, or a wait-
and-see policy for tendinopathy of the main body of
tendo Achillis: a randomized controlled trial.” [4];
and
• “A randomized controlled trial of extracorporeal
shock wave therapy for lateral epicondylitis (tennis
elbow).” [9].
Note that these indications are anatomically deWned dis-
eases of attachment sites (“entheses”) where tendons and
ligaments meet bone, i.e., regions with a very speciWc
pathology and pathophysiology [12].
2. Several molecular and cellular mechanisms were
reported recently on how extracorporeal shock waves
might mediate their pain-relieving action (again, refer-
ence was made to speciWc titles of studies published in
the international peer-reviewed literature):
• “Substance P and prostaglandin E2 release after shock
wave application to the rabbit femur.” [13];
• “Extracorporeal shockwave application to the distal
femur of rabbits diminishes the number of neurons
immunoreactive for substance P in dorsal root ganglia
L5.” [14];
• “Application of shock waves to rat skin decreases cal-
citonin gene-related peptide (CGRP) immunoreactiv-
ity in dorsal root ganglion neurons.” [15]; and
• “Selective loss of unmyelinated nerve Wbers after
extracorporeal shockwave application to the musculo-
skeletal system.” [16].
Substance P is concentrated in unmyelinated C-Wbers and a
subpopulation of slowly conducting, lightly myelinated A-
nerve Wbers, and is released at central and peripheral termi-
nals of sensory nociceptive neurons after stimulation [17–
19]. CGRP is a marker of sensory neurons typically
involved with pain perception and was immunohistochemi-
cally co-localized with substance P in capsaicin-sensitive
axons [20]. Activation of peripheral small diameter sensory
neurons by local depolarization, axonal reXexes or dorsal
root reXexes releases substance P and CGRP. Both sub-
stances then act on target cells in the periphery such as mast
cells, immune cells and vascular smooth muscle cells, thus
producing inXammation. This phenomenon is called neuro-
genic inXammation, and is, an inXammatory symptom that
results from the release of substances from primary sensory
nerve terminals [21,  22]. Evidence has emerged that
chronic inXammation contributes to the etiology of pain in
tennis elbow and chronic plantar fasciitis [23–27]. Further-
more, a recent study revealed the contribution of substance
P (as well as interleukin 1 alpha and transforming growth
factor beta1) in the pathogenesis of tennis elbow, without
apparent inWltration of inXammatory cells [28]. Moreover,
depletion of substance P was shown repeatedly to reduce
experimentally induced inXammation of paws and joints in
laboratory animals [29–31]. It is therefore reasonable to
hypothesize that (1) neurogenic inXammation plays an
important role in the pathogenesis of tennis elbow and
chronic plantar fasciitis, and (2) reduction of substance P in
the target tissue [13] in conjunction with reduced synthesis
of this molecule in dorsal root ganglia cells [14] plays an
important role in ESWT-mediated long-term analgesia in
the treatment of these diseases. Selective destruction of
unmyelinated nerve Wbers within the focal zone of the
shock waves [16] might also contribute to this analgesia.
Also important to mention is that unmyelinated C-Wbers are
known to be responsible for throbbing, chronic pain [32].
3. One can only speculate as to Dr. Wess’ motivation to
publish his hypothesis [1] without any reference to the
detailed knowledge existing in the international peer-
reviewed literature outlined above. An interesting indi-
cation in this regard might emerge from the fact that
Dr. Wess is aYliated with Storz Medical AG
(Tägerwillen, Switzerland), the manufacturer of sev-
eral extracorporeal shock wave systems (among them
the D-ACTOR 200 marketed in the USA [33]). The US
Food and Drug Administration (FDA) classiWes extra-
corporeal shock wave therapy devices as Class III,
highest risk devices. According to FDA, the risk the
type of device poses to the patient or the user is a major
factor in the class it is assigned [34]. Approval of a
Class III device requires demonstration of clinical
eYcacy and safety in a so-called “investigationalUrol Res (2009) 37:231–234 233
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device exemption” (IDE) study. Based on the results of
this study, FDA then grants “pre-market approval”
(PMA) to the manufacturer to market the device in the
US marketplace.
To date (25 February 2009), the following extracorporeal
shock wave devices have been granted PMA by FDA:
• OssaTron (HealthTronics, Inc., Marietta, GA, USA);
PMA no. P990086 issued on 12 October 2000 to treat
chronic heel pain [35];
• Dornier Epos Ultra (Dornier Medical Systems, Inc.,
Kennesaw, GA, USA); PMA no. P000048 issued on 15
January 2001 for treatment of chronic plantar fasciitis for
patients with symptoms of plantar fasciitis for 6 months
or more and a history of unsuccessful conservative
therapy [36];
• Siemens SONOCUR Basic (Siemens Medical Solutions,
Inc., Iselin, NJ, USA); PMA no. P010039 issued on 19
July 2002 for treatment for pain due to tennis elbow [37];
• Orthospec Extracorporeal Shock Wave Therapy (Medi-
spec, Ltd; Germantown, MD, USA); PMA no. P040026
issued 1 April 2005 for treatment of proximal plantar fas-
ciitis with or without heel spur in patients 18 years of age
or older [38];
• Orbasone Pain Relief System (Orthometrix, Inc., White
Plains, NY, USA); PMA no. P040039 issued on 10
August 2005 to relieve heel pain (proximal plantar fasci-
itis) [39]; and
• EMS Swiss DolorClast (EMS Electro Medical Systems,
Nyon Switzerland); PMA no. P050004 issued on 8 May
2007 to treat heel pain associated with chronic proximal
plantar fasciitis [40].
In contrast, the extracorporeal shock wave system
D-ACTOR 200 has been presented to FDA as Class I medi-
cal device, predicated on a similar function and purpose to
“Therapeutic Massagers” (Regulation Number 890.5660
within Title 21 of the Code of Federal Regulations (CFR)
[41]. As a result, the D-ACTOR has been granted 510[k]
Premarket NotiWcation by FDA as a Class I “Massager, Ther-
apeutic, Electric” (510[k] no. K072809; decision date 27
June 2008) [42]. It remains unknown whether clinical
eYcacy and safety of ESWT treatment with the D-ACTOR
200 has been demonstrated in an IDE study; corresponding
data has not been published in the international peer-
reviewed literature. Note that 510[k] Premarket NotiWcation
of Class I devices usually does not require a medical device
manufacturer to perform an IDE study and present the results
to FDA. The reason for this is that FDA considers Class I
submissions as “lowest risk” devices that may bypass the
lengthy and costly trials needed to enter the US marketplace.
Examples of Class I medical devices include: tongue depres-
sors, elastic bandages, reading glasses and forceps [34].
Appendix G of the 510(k) Premarket NotiWcation of the
D-ACTOR 200 indicates that this medical device is
intended for the following: (2) to relieve minor muscle
aches and pains, and (2) for the temporary increase in local
blood circulation [42]. This is in striking contrast to all
other extracorporeal shock wave devices listed above
whose use is clearly intended for treating pain associated
with anatomically deWned disorders. The latter, however, is
not the purpose of Therapeutic Massagers regulated by
FDA under Regulation Number 890.5660 within CFR Title
21 [41]. In other words, FDA has not speciWed that Thera-
peutic Massagers may be used for the treatment of the ana-
tomically deWned diseases as discussed in this letter. This is
also in line with the fact that no evidence exists in the inter-
national peer-reviewed literature that Therapeutic Massag-
ers exert their biomedical actions on the musculoskeletal
system by the molecular and cellular mechanisms outlined
above. Rather, anatomically deWned diseases such as
chronic plantar fasciitis and chronic Achilles tendinopathy
are discussed in the current international peer-reviewed lit-
erature as potential indications for treatment with extracor-
poreal shock waves but not with Therapeutic Massagers
[43, 44].
In summary, the modern concept of ESWT for various
indications of the musculoskeletal system is based on the
principles of molecular cell biology and clinical evidence
based medicine, witnessed by numerous publications in the
international peer-reviewed literature. Dr. Wess’ hypothe-
sis [1] does not refer to this knowledge and should be eval-
uated cautiously against the fact that the extracorporeal
shock wave system D-ACTOR 200 manufactured by Storz
Medical AG (Dr. Wess’ aYliation) has not been presented
to FDA as a Class III extracorporeal shock wave device but
rather as Class I device, being similar in function and pur-
pose to Therapeutic Massagers.
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